FDA

health care

ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep Vein Thrombosis and Pulmonary ...
Read Full Story »
186171981

Can Tekmira Make Much Money From Its Ebola Treatment?

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) has made a name for itself pioneering new experimental treatments in the wake of the most recent Ebola scare. Ebola is considered one of the deadliest ...
Read Full Story »
biotech

Should Investors Really Be Chasing Potential Ebola Treatments?

The world is dealing with Ebola outbreaks and scares again. We are also in the midst of debates as to whether two Americans who contracted Ebola in Africa should have been ...
Read Full Story »
biotech

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

A brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The ...
Read Full Story »
biotech

4 Key Positive Biotech Stock Catalysts Coming Very Soon

Investors and speculators often flock to the world biotech for emerging drugs of the future. It is no secret at all that the biotech sector is full of all sorts ...
Read Full Story »
biotech

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

Over the years biotech investors who have owned the right stocks have made some very big money on Federal Drug Administration (FDA) approval of leading drug candidates. Typically biotech firms ...
Read Full Story »
76764023

Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?

MannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 ...
Read Full Story »
biotech

Why Insmed Could Still Double

Insmed Inc. (NASDAQ: INSM) shares were screaming higher on Wednesday. This is just days after we featured it this last weekend as one of three stocks that could double. While ...
Read Full Story »
76764023

The MannKind Lifeline Lights Up

MannKind Corp. (NASDAQ: MNKD) could have been and should have been featured in our Analyst Stocks to Buy Under $10 For Huge Upside this weekend, but MannKind is such a ...
Read Full Story »
153576724

Orexigen Irony: No VIVUS Bounce

VIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America's ballooning waistline is reaching a critical level, yet VIVUS did not even manage to close ...
Read Full Story »
Pills

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

Binary events in the health care arena can be huge in determining just how well investors do and their stocks perform. Medical meetings, clinical data and of, course, decisions by ...
Read Full Story »
biotech

As GW Pharma Gets Fast Track, Is FDA More Open to Medical Marijuana?

GW Pharmaceuticals PLC (NASDAQ: GWPH) was one of the stocks surging on Friday, on news that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation status to ...
Read Full Story »
DNA

Halozyme Gets New Hope for Shareholders, and for Pancreatic Cancer Patients

Halozyme Therapeutics Inc. (NASDAQ: HALO) saw its stock surge on Thursday on news reports that the U.S. Food and Drug Administration (FDA) has removed its clinical hold on patient enrollment ...
Read Full Story »
sunset empy road

Are Tanning Bed Risks the New Cigarettes?

The Food & Drug Administration has just put another dark cloud over the business of tanning booths. This FDA issue is a final order which reclassifies sunlamp products and ultraviolet ...
Read Full Story »
philip morris cigarette manufacturing

Big Tobacco Dividends Come Under FDA E-cigarette Regulation, Maybe

The U.S. Food & Drug Administration (FDA) has come out and proposed to extend its tobacco authority to additional tobacco products, including e-cigarettes. What the public needs to know is ...
Read Full Story »